Mechanisms leading to the development of hormone-resistant prostate cancer

被引:52
|
作者
Kasper, Susan [1 ]
Cookson, Michael S. [1 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN 37232 USA
关键词
D O I
10.1016/j.ucl.2005.12.010
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Advanced and metastatic prostate cancers remain potentially lethal tumors. Although androgen deprivation therapy remains the most effective treatment, patients who progress to androgen independence die of their disease. This article focuses on the mechanisms by which hormone resistance develops, including the reactivation of androgen receptor during androgen deprivation therapy, the role of cancer stem cells, and the emergence of epithelial-mesenchymal transition cells, which have increased metastatic potential. It is through an enhanced understanding of these mechanisms that new therapies can be developed to combat this disease.
引用
收藏
页码:201 / +
页数:11
相关论文
共 50 条
  • [1] Hormone-resistant prostate cancer
    Khoury, S
    [J]. PROGRES EN UROLOGIE, 2002, 12 (01): : 7 - 18
  • [2] Introduction - Hormone-resistant prostate cancer
    Coulange, C
    Khoury, S
    [J]. PROGRES EN UROLOGIE, 2002, 12 (01): : 5 - 5
  • [3] Pathophysiology of hormone-resistant prostate cancer
    Belev, Borislav
    Sipic, Tomislav
    [J]. PERIODICUM BIOLOGORUM, 2014, 116 (04) : 387 - 392
  • [4] Gene amplifications associated with the development of hormone-resistant prostate cancer
    Edwards, J
    Krishna, S
    Witton, CJ
    Bartlett, JMS
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (14) : 5271 - 5281
  • [5] New findings for hormone-resistant prostate cancer
    Kerr, C
    [J]. LANCET ONCOLOGY, 2006, 7 (04): : 292 - 292
  • [6] Challenges and Opportunities in Hormone-Resistant Prostate Cancer
    Miller, Kurt
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (01) : 36 - 45
  • [7] PROGNOSTIC FACTORS IN HORMONE-RESISTANT PROGRESSING CANCER OF THE PROSTATE
    FOSSA, SD
    DEARNALEY, DP
    LAW, M
    GAD, J
    NEWLING, DWW
    TVETER, K
    [J]. ANNALS OF ONCOLOGY, 1992, 3 (05) : 361 - 366
  • [9] Management of hormone-resistant prostate cancer: An Australian trial
    Raghavan, D
    Coorey, G
    Rosen, M
    Page, J
    Farebrother, T
    [J]. SEMINARS IN ONCOLOGY, 1996, 23 (06) : 20 - 23
  • [10] Weekly epirubicin in patients with hormone-resistant prostate cancer
    Petrioli, R
    Fiaschi, AL
    Pozzessere, D
    Messinese, S
    Sabatino, M
    Marsili, S
    Correale, P
    Manganelli, A
    Salvestrini, F
    Francini, G
    [J]. BRITISH JOURNAL OF CANCER, 2002, 87 (07) : 720 - 725